Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):41–48. doi: 10.1097/QAI.0b013e3182632540

FIGURE 3.

FIGURE 3

The risk of treatment failure and death on secondline ART containing and not containing tenofovir in Zambia and the Republic of South Africa. The estimates shown are hazard ratios (HR) for immunological and virological failure and subdistribution hazard ratios (sHR) for mortality.